Collin Maloney
Physician Assistant · Syracuse, NYNPI 1831505148
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,019 of the $56,966 with a category attached, or 87.8%. 23 manufacturers reported payments, led by AbbVie at 52.0% of the total. Reporting peaked in 2021 at $40,695 and has fallen 97.0% since, to $1,217 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $123.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Biohaven Pharmaceuticals, Inc.$20K
- Biohaven Pharmaceutical Holding Company Ltd.$4K
- Pfizer$675
- UCB, Inc.$445
- Teva Pharmaceuticals USA, Inc.$282
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$50,01988%
- Travel & lodging$4361%
- Food & beverage$6,51211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 207 | $29,596 |
| Biohaven Pharmaceuticals, Inc. | 48 | $20,352 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $4,027 |
| Pfizer | 64 | $675 |
| UCB, Inc. | 20 | $445 |
| Teva Pharmaceuticals USA, Inc. | 14 | $282 |
| Lilly USA, LLC | 14 | $275 |
| Catalyst Pharmaceuticals, Inc. | 11 | $234 |
| SK Life Science, Inc. | 9 | $208 |
| Biogen | 6 | $134 |
| Novartis | 16 | $115 |
| Eisai Inc. | 5 | $112 |
| Neurelis, Inc. | 5 | $108 |
| Bristol Myers Squibb | 3 | $62 |
| AstraZeneca | 3 | $54 |
| Genentech USA, Inc. | 3 | $53 |
| Amgen | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $43 |
| Upsher-smith Laboratories LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Abbott | 1 | $24 |
| Sumitomo Pharma America, Inc. | 2 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$24,350
- NURTEC ODT$23,461
- BOTOX$3,099
How this compares
$56,966 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 139 | $97,793 |
| Aimovig AutoinjectorErenumab-Aooe | 104 | $83,756 |
| Nurtec OdtRimegepant Sulfate | 79 | $74,261 |
| UbrelvyUbrogepant | 58 | $57,324 |
| QuliptaAtogepant | 44 | $55,343 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 48 | $40,374 |
| BriviactBrivaracetam | 17 | $24,153 |
| XcopriCenobamate | 11 | $14,670 |
| EliquisApixaban | 12 | $14,552 |
| Levetiracetam | 279 | $8,390 |
| Lacosamide | 75 | $8,263 |
| Zolmitriptan | 46 | $8,030 |
| Lamotrigine ErLamotrigine | 14 | $6,243 |
| DilantinPhenytoin Sodium Extended | 13 | $3,948 |
| Topiramate | 297 | $3,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $29,596 | $112,668102 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $675 | $92,761104 claims |
| UCB, Inc.Briviact | $445 | $24,15317 claims |
| SK Life Science, Inc.Xcopri | $208 | $14,67011 claims |
| Upsher-smith Laboratories LLCTopiramate | $28 | $3,834297 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Syracuse
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
- Julius NwosuBronx$256K
- Cameron KiserNew York$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.